Dianthus Therapeutics vs Edgewise Therapeutics
Dianthus Therapeutics (DNTH), health care, and Edgewise Therapeutics (EWTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Key facts
- Dianthus Therapeutics revenue
- $2MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
No live quote for Dianthus Therapeutics or Edgewise Therapeutics could be read just now, so their market value, valuation ratios and price changes show as —. The annual figures stand.
| Measure | Dianthus Therapeutics | Edgewise Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | — | — |
| Revenue | $2M | — |
| Earnings | -$162.3Mhigher | -$167.8Mlower |
| Employees | 92lower | 133higher |
| Total assets | $530.9Mlower | $552.6Mhigher |
| Valuation | ||
| P/E | — | — |
| P/S | — | — |
| P/B | — | — |
| Dividend yield | — | — |
| Profitability | ||
| Operating margin | -8739% | — |
| Balance sheet | ||
| Net assets | $493.4Mlower | $522.3Mhigher |
| Total liabilities | $37.5Mhigher | $30.3Mlower |
| Total debt | — | — |
| Cash on hand | $51.1Mlower | $61.1Mhigher |
| Price change | ||
| Today | — | — |
| 1 year | — | — |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Julian and Felix Baker0.4% / 0.8%
Dianthus Therapeutics only (1)
- Polen Capital team<0.1%
Edgewise Therapeutics only (1)
- Peter Kolchinsky3.0%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Dianthus Therapeutics / Edgewise Therapeutics). Who owns DNTH · Who owns EWTX
More on Dianthus Therapeutics
Further comparisons
Dianthus Therapeutics against its closest peers
Edgewise Therapeutics against its closest peers
Learn
Questions and answers
Which superinvestors own both Dianthus Therapeutics and Edgewise Therapeutics?
In their latest 13F filings, Julian and Felix Baker holds both.
Cite this page
Funkfolio, “Dianthus Therapeutics vs Edgewise Therapeutics”, data as of 17 November 2026. https://funkfolio.com/compare/dnth-vs-ewtx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.